Free Trial

Savara (SVRA) Competitors

Savara logo
$2.58 +0.03 (+1.18%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.00 (+0.19%)
As of 07/25/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SVRA vs. JANX, ETNB, EVO, VERA, ANIP, BHVN, TVTX, EWTX, COGT, and SRPT

Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Janux Therapeutics (JANX), 89BIO (ETNB), Evotec (EVO), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Biohaven (BHVN), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), Cogent Biosciences (COGT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.

Savara vs. Its Competitors

Savara (NASDAQ:SVRA) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

87.9% of Savara shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Janux Therapeutics' return on equity of -9.29% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
SavaraN/A -65.88% -52.35%
Janux Therapeutics N/A -9.29%-8.89%

Janux Therapeutics has higher revenue and earnings than Savara. Janux Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SavaraN/AN/A-$95.88M-$0.48-5.38
Janux Therapeutics$10.59M145.05-$68.99M-$1.36-19.09

Savara presently has a consensus price target of $5.60, indicating a potential upside of 117.05%. Janux Therapeutics has a consensus price target of $91.89, indicating a potential upside of 253.96%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Savara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Savara
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Janux Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.08

Savara has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500.

In the previous week, Janux Therapeutics had 3 more articles in the media than Savara. MarketBeat recorded 7 mentions for Janux Therapeutics and 4 mentions for Savara. Janux Therapeutics' average media sentiment score of 1.27 beat Savara's score of 0.75 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Savara
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Janux Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Janux Therapeutics beats Savara on 12 of the 15 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVRA vs. The Competition

MetricSavaraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$440.73M$2.50B$5.70B$9.50B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-5.379.0528.1020.06
Price / SalesN/A592.38428.7189.11
Price / CashN/A165.2136.2258.56
Price / Book2.585.168.665.87
Net Income-$95.88M$30.99M$3.25B$258.55M
7 Day Performance14.16%7.74%4.22%3.73%
1 Month Performance16.74%16.27%10.51%11.75%
1 Year Performance-42.15%-1.88%34.40%18.02%

Savara Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVRA
Savara
1.8402 of 5 stars
$2.58
+1.2%
$5.60
+117.1%
-43.7%$440.73MN/A-5.3720
JANX
Janux Therapeutics
2.471 of 5 stars
$26.08
-1.2%
$91.89
+252.3%
-39.3%$1.56B$10.59M0.0030
ETNB
89BIO
1.8565 of 5 stars
$10.11
-3.6%
$26.43
+161.4%
-0.7%$1.53BN/A0.0040
EVO
Evotec
2.028 of 5 stars
$3.69
-13.4%
$5.93
+60.8%
-9.6%$1.51B$862.40M0.004,827Gap Up
High Trading Volume
VERA
Vera Therapeutics
4.2816 of 5 stars
$22.79
-1.1%
$65.00
+185.2%
-40.8%$1.47BN/A0.0040Positive News
ANIP
ANI Pharmaceuticals
3.8572 of 5 stars
$65.41
-1.3%
$78.88
+20.6%
+8.8%$1.44B$614.38M-51.50600
BHVN
Biohaven
2.3164 of 5 stars
$13.81
-1.7%
$58.46
+323.5%
-66.4%$1.43BN/A-1.47239Trending News
TVTX
Travere Therapeutics
2.961 of 5 stars
$15.82
-1.8%
$32.14
+103.2%
+56.8%$1.43B$233.18M0.00460Upcoming Earnings
EWTX
Edgewise Therapeutics
1.6647 of 5 stars
$13.39
-1.1%
$40.00
+198.7%
-24.6%$1.42BN/A0.0060
COGT
Cogent Biosciences
3.5614 of 5 stars
$12.30
-1.5%
$18.70
+52.0%
+30.9%$1.42BN/A-6.6880
SRPT
Sarepta Therapeutics
4.6958 of 5 stars
$13.32
-5.3%
$54.33
+307.9%
-91.9%$1.38B$1.90B0.001,372Trending News
Analyst Downgrade
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SVRA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners